Yoshino T - Search Results

1

Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.

André T, Meyerhardt J, Iveson T, Sobrero A, Yoshino T, Souglakos I, Grothey A, Niedzwiecki D, Saunders M, Labianca R, Yamanaka T, Boukovinas I, Vernerey D, Meyers J, Harkin A, Torri V, Oki E, Georgoulias V, Taieb J, Shields A, Shi Q. André T, et al. Among authors: yoshino t. Lancet Oncol. 2020 Dec;21(12):1620-1629. doi: 10.1016/S1470-2045(20)30527-1. Lancet Oncol. 2020. PMID: 33271092 Free PMC article.

2

[IFL].

Yamazaki K, Yoshino T, Boku N. Yamazaki K, et al. Among authors: yoshino t. Gan To Kagaku Ryoho. 2006 Jul;33(7):907-10. Gan To Kagaku Ryoho. 2006. PMID: 16835478 Review. Japanese.

3

Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.

Yoshino T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yamaguchi Y, Hasuike N, Yamazaki K, Machida N, Ono H. Yoshino T, et al. Jpn J Clin Oncol. 2007 Sep;37(9):686-91. doi: 10.1093/jjco/hym091. Epub 2007 Aug 24. Jpn J Clin Oncol. 2007. PMID: 17720736

4

Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.

Machida N, Yoshino T, Boku N, Hironaka S, Onozawa Y, Fukutomi A, Yamazaki K, Yasui H, Taku K, Asaka M. Machida N, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2008 Oct;38(10):689-94. doi: 10.1093/jjco/hyn086. Jpn J Clin Oncol. 2008. PMID: 18845522

5

A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer.

Muro K, Yoshino T, Doi T, Shirao K, Takiuchi H, Hamamoto Y, Watanabe H, Yang BB, Asahi D. Muro K, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2009 May;39(5):321-6. doi: 10.1093/jjco/hyp016. Epub 2009 Mar 14. Jpn J Clin Oncol. 2009. PMID: 19287023 Clinical Trial.

6

Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1).

Ono A, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yasui H, Yamazaki K, Yoshino T, Taku K, Kojima T. Ono A, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2009 May;39(5):332-5. doi: 10.1093/jjco/hyp018. Epub 2009 Mar 24. Jpn J Clin Oncol. 2009. PMID: 19318372

7

Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.

Mochizuki S, Yoshino T, Kojima T, Fuse N, Ikematsu H, Minashi K, Yano T, Tahara M, Kaneko K, Doi T, Koike K, Ohtsu A. Mochizuki S, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2010 Oct;40(10):933-7. doi: 10.1093/jjco/hyq058. Epub 2010 May 21. Jpn J Clin Oncol. 2010. PMID: 20494948

8

Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.

Ikeda E, Kojima T, Kaneko K, Minashi K, Onozawa M, Nihei K, Fuse N, Yano T, Yoshino T, Tahara M, Doi T, Ohtsu A. Ikeda E, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2011 Aug;41(8):964-72. doi: 10.1093/jjco/hyr088. Epub 2011 Jul 7. Jpn J Clin Oncol. 2011. PMID: 21742654

9

FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study).

Mishima H, Oba K, Sakamoto J, Muro K, Yoshino T, Hyodo I, Maehara Y. Mishima H, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2012 Feb;42(2):134-8. doi: 10.1093/jjco/hyr180. Epub 2011 Dec 12. Jpn J Clin Oncol. 2012. PMID: 22167662 Free PMC article. Clinical Trial.

10

Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer.

Yoshino T, Yamazaki K, Hamaguchi T, Shimada Y, Kato K, Yasui H, Boku N, Lechuga MJ, Hirohashi T, Shibata A, Hashigaki S, Li Y, Ohtsu A. Yoshino T, et al. Anticancer Res. 2012 Mar;32(3):973-9. Anticancer Res. 2012. PMID: 22399619 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,055 results

Search Page